Details for Patent: 9,175,017
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,175,017 protect, and when does it expire?
Patent 9,175,017 protects NINLARO and is included in one NDA.
This patent has one hundred and twenty-three patent family members in thirty-seven countries.
Summary for Patent: 9,175,017
Title: | Boronate ester compounds and pharmaceutical compositions thereof |
Abstract: | The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. |
Inventor(s): | Elliott; Eric L. (Brighton, MA), Ferdous; Abu J. (Winchester, MA), Kaufman; Michael J. (Lexington, MA), Komar; Sonja A. (Belmont, MA), Mazaik; Debra L. (Holliston, MA), McCubbin; Quentin J. (Belmont, MA), Nguyen; Phuong M. (Cambridge, MA), Palaniappan; Vaithianathan (Andover, MA), Skwierczynski; Raymond D. (Andover, MA), Truong; Nobel T. (Milford, MA), Varga; Csanad M. (Newton, MA), Zawaneh; Peter N. (Cambridge, MA) |
Assignee: | |
Application Number: | 14/449,275 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,175,017 |
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; Delivery; |
Drugs Protected by US Patent 9,175,017
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-001 | Nov 20, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | See Plans and Pricing | ||||
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-002 | Nov 20, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | See Plans and Pricing | ||||
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-003 | Nov 20, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,175,017
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 072162 | See Plans and Pricing | |||
Argentina | 095554 | See Plans and Pricing | |||
Argentina | 095566 | See Plans and Pricing | |||
Argentina | 100011 | See Plans and Pricing | |||
Australia | 2009260778 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |